









市场行情
/
股票
/
nasdaq-wve
/

WAVE Life Sciences Ltd

WVE

17.000USD

-0.150-0.87%

收盘 12/31, 16:00（美东）报价延迟15分钟

2.72B总市值

亏损市盈率 TTM



WAVE Life Sciences Ltd

17.000

-0.150-0.87%

概览公司财务分析

概览

公司

财务

分析

关于 WAVE Life Sciences Ltd 公司

Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the broad potential of ribonucleic acid (RNA) medicines to transform human health. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).

WAVE Life Sciences Ltd简介



公司代码WVE

公司名称WAVE Life Sciences Ltd

上市日期Nov 11, 2015

CEOBolno (Paul B)

员工数量287

证券类型Ordinary Share

年结日Nov 11

公司地址7 Straits View

城市

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Singapore

邮编018936

电话6562363388

网址https://www.wavelifesciences.com/

公司代码WVE

上市日期Nov 11, 2015

CEOBolno (Paul B)

WAVE Life Sciences Ltd公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Chandra Vargeese, Ph.D.

Chief Technology Officer, Head - Platform Discovery Sciences

302.31K

Mr. Kyle Moran

Chief Financial Officer

60.96K

+143.86%

Ms. Heidi L. Wagner, J.D.

Independent Director

28.82K

Ms. Aik Na Tan

Independent Director

25.40K

-37.11%

Mr. Ken Takanashi

Independent Director

23.94K

+48.58%

Mr. Christian O. Henry

Independent Chairman of the Board

12.70K

-33.66%

Dr. Paul B. Bolno, M.D.

President, Chief Executive Officer, Director

Dr. Christopher John Francis, Ph.D.

Senior Vice President - Corporate Development, Head - Emerging Areas

Dr. Gregory L. (Greg) Verdine, Ph.D.

Director

Dr. Peter Kolchinsky, Ph.D.

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Chandra Vargeese, Ph.D.

Chief Technology Officer, Head - Platform Discovery Sciences

302.31K

Mr. Kyle Moran

Chief Financial Officer

60.96K

+143.86%

Ms. Heidi L. Wagner, J.D.

Independent Director

28.82K

Ms. Aik Na Tan

Independent Director

25.40K

-37.11%

Mr. Ken Takanashi

Independent Director

23.94K

+48.58%

Mr. Christian O. Henry

Independent Chairman of the Board

12.70K

-33.66%

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月15日周六

持股股东

股东类型

持股股东

占比

GSK plc

9.98%

RA Capital Management, LP

9.97%

Adage Capital Management, L.P.

7.97%

BlackRock Institutional Trust Company, N.A.

4.78%

Maverick Capital, Ltd.

4.59%

其他

62.71%

持股股东

占比

GSK plc

9.98%

RA Capital Management, LP

9.97%

Adage Capital Management, L.P.

7.97%

BlackRock Institutional Trust Company, N.A.

4.78%

Maverick Capital, Ltd.

4.59%

其他

62.71%

股东类型

持股股东

占比

Investment Advisor

29.00%

Hedge Fund

21.22%

Investment Advisor/Hedge Fund

16.23%

Corporation

14.13%

Venture Capital

10.06%

Research Firm

1.89%

Individual Investor

0.41%

Bank and Trust

0.23%

Pension Fund

0.21%

其他

6.61%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

368

140.86M

88.47%

+5.01M

2025Q2

364

156.69M

98.46%

-1.61M

2025Q1

368

156.82M

101.38%

+1.16M

2024Q4

342

152.89M

100.27%

+6.14M

2024Q3

306

144.44M

97.59%

+25.71M

2024Q2

274

116.00M

94.13%

+429.46K

2024Q1

255

115.83M

95.69%

+2.66M

2023Q4

240

115.18M

98.42%

+19.70M

2023Q3

224

93.79M

97.86%

+5.83M

2023Q2

224

93.41M

97.80%

+7.66M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

GSK plc

16.78M

10.54%

Jun 06, 2025

RA Capital Management, LP

18.21M

11.44%

+12.70K

+0.07%

Aug 11, 2025

Adage Capital Management, L.P.

15.02M

9.43%

+2.50M

+19.97%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

8.75M

5.5%

+540.89K

+6.59%

Jun 30, 2025

Maverick Capital, Ltd.

8.26M

5.19%

Jun 30, 2025

Driehaus Capital Management, LLC

6.53M

4.1%

+172.92K

+2.72%

Jun 30, 2025

Shin Nippon Biomedical Laboratories Ltd

5.71M

3.58%

Jun 06, 2025

M28 Capital Management LP

5.66M

3.56%

Jun 30, 2025

Emerald Advisers LLC

5.19M

3.26%

+130.23K

+2.57%

Jun 30, 2025

Kynam Capital Management LP

4.56M

2.86%

-339.44K

-6.93%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

State Street SPDR S&P Pharmaceuticals ETF

1.81%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.34%

Global X Genomics & Biotechnology ETF

1.25%

Virtus LifeSci Biotech Clinical Trials ETF

0.85%

iShares U.S. Pharmaceuticals ETF

0.41%

First Trust Multi-Manager Small Cap Opportunities ETF

0.26%

iShares Micro-Cap ETF

0.19%

Franklin Genomic Advancements ETF

0.19%

ProShares Ultra Nasdaq Biotechnology

0.15%

Invesco Nasdaq Biotechnology ETF

0.14%

State Street SPDR S&P Pharmaceuticals ETF

占比1.81%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比1.34%

Global X Genomics & Biotechnology ETF

占比1.25%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.85%

iShares U.S. Pharmaceuticals ETF

占比0.41%

First Trust Multi-Manager Small Cap Opportunities ETF

占比0.26%

iShares Micro-Cap ETF

占比0.19%

Franklin Genomic Advancements ETF

占比0.19%

ProShares Ultra Nasdaq Biotechnology

占比0.15%

Invesco Nasdaq Biotechnology ETF

占比0.14%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

WAVE Life Sciences Ltd的前五大股东是谁？



WAVE Life Sciences Ltd 的前五大股东如下：
GSK plc持有股份：16.78M，占总股份比例：10.54%。
RA Capital Management, LP持有股份：18.21M，占总股份比例：11.44%。
Adage Capital Management, L.P.持有股份：15.02M，占总股份比例：9.43%。
BlackRock Institutional Trust Company, N.A.持有股份：8.75M，占总股份比例：5.50%。
Maverick Capital, Ltd.持有股份：8.26M，占总股份比例：5.19%。